Predicting progression to active tuberculosis: A rate-limiting step on . . . A World Health Organization (WHO) consensus statement identified an optimal target product profile that should predict risk of progression to TB within two years after infection with sensitivity and specificity ≥90% or at least ≥75%, a high PPV, and a low NNT
Latent tuberculosis infection: An overview - canada. ca Preventing the progression of LTBI to active TB disease is an important public health goal that can substantially reduce TB transmission A key part of the End TB Strategy is targeted treatment of those infected and who are at risk for progression to active TB disease
Latent tuberculosis infection - World Health Organization (WHO) Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens with no evidence of clinically manifest active TB There is no gold standard test for LTBI The WHO guidelines on LTBI consider the probability of progression to active TB disease in a
Can we predict progression from latent to active TB? - TeachEpi All existing LTBI tests (TST and IGRAs) have only modest predictive value and may not help identify those who are at highest risk of progression to disease How can we squeeze predictive value out of LTBI tests? Used unbiased high-throughput screening of host blood RNA profiles to identify new signatures of risk for TB
Executive summary - Latent tuberculosis infection: updated and . . . The WHO guidelines on LTBI consider the probability of progression to active TB disease in a specific risk group, the epidemiology and burden of TB, the availability of resources and the likelihood of a broad public health impact
Assessing the risk of TB progression: Advances in blood-based biomarker . . . LTBI individuals showed significantly increased KLRG1 + NK cells compared to active TB patients, while MTB-specific IFN-γ+CD56 Bright CD16 Dim NK cells expressed higher KLRG1 in TB cases, indicating a phenotype modulating the progression from latent to active TB (Harris et al , 2020)